By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Cerenis Therapeutics, Inc. 

900 Victors Way
Suite 280
Ann Arbor  Michigan  48108  U.S.A.
Phone: 734-769-1110 Fax: 734-769-1132



Company News
Cerenis Therapeutics, Inc. Receives FDA IND Approval To Begin Studies With CER-209 In NAFLD And NASH 12/16/2016 11:40:32 AM
Cerenis Therapeutics, Inc. Announces Last Patient Dosed In CARAT Phase II Study With CER-001 In Post-Acute Coronary Syndrome Patients 11/8/2016 11:06:20 AM
Cerenis Therapeutics, Inc. Release: Publication Of The Location Clinical Study Results In The Renowned Scientific Journal Of The European Atherosclerosis Society 6/2/2016 11:48:23 AM
Cerenis Therapeutics, Inc. Featured Prominently At The 25th Conference Of The Asian Pacific Association For The Study Of The Liver (APASL) 2/25/2016 2:27:18 PM
Catalent Biologics And Cerenis Therapeutics, Inc. Announce Phase III Trial Of CER-001 In Europe And North America Leveraging GPEx Cell Line Technology 1/28/2016 10:40:56 AM
Cerenis Therapeutics, Inc.: New Data For CER-001 Presented In Key Oral Session At American Heart Association Conference 2015 11/10/2015 12:55:24 PM
Cerenis Therapeutics, Inc. Announces The Results Of The LOCATION Study 7/15/2015 9:42:14 AM
Cerenis Therapeutics, Inc. Announces The Appointment Of A New Chief Medical Officer And New Board Members 2/9/2015 11:00:36 AM
Cerenis Therapeutics, Inc. Receives European Medicines Agency Orphan Drug Designations For CER-001 For The Treatment Of ApoA-I And ABCA-1 Deficiencies 9/3/2014 12:44:17 PM
Cerenis Therapeutics, Inc. Appoints Dr. Richard C. Pasternak As Chairman 9/3/2014 10:59:52 AM